Mark E. Burkard, MD, PhD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Mark Burkard is an assistant professor of medicine in the Hematology-Oncology section of the UW School of Medicine and Public Health and is a member of the UW Health Breast Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester. He subsequently trained in internal medicine at New York Hospital-Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. During his oncology fellowship, he studied cell cycle enzymes as novel targets for cancer therapy. He is board certified in Internal Medicine and Medical Oncology. As an oncologist, his clinical practice and research interest is in breast cancer and experimental therapeutics.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
Memorial Sloan-Kettering Cancer Center, New York, NY
University of Rochester School of Medicine, Rochester, NY, 2002
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Programs & Conditions
Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G .
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016 Jun 1;22(11):2659-67
[PubMed ID: 27026198]
Lera RF Potts GK Suzuki A Johnson JM Salmon ED Coon JJ Burkard ME .
Decoding Polo-like kinase 1 signaling along the kinetochore-centromere axis. Nat Chem Biol. 2016 Jun;12(6):411-8
[PubMed ID: 27043190]
Wisinski KB Xu W Tevaarwerk AJ Saha S Kim K Traynor A Dietrich L Hegeman R Patel D Blank J Harter J Burkard ME .
Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clin Breast Cancer. 2016 Mar 31;
[PubMed ID: 27133732]
Denu RA Zasadil LM Kanugh C Laffin J Weaver BA Burkard ME .
Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer. 2016 Jan 29;16:47
[PubMed ID: 26832928]
Choudhary A Zachek B Lera RF Zasadil LM Lasek A Denu RA Kim H Kanugh C Laffin JJ Harter JM Wisinski KB Saha S Weaver BA Burkard ME .
Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. Mol Cancer Ther. 2016 Jan;15(1):48-59
[PubMed ID: 26586723]
Lasek AL McPherson BM Trueman NG Burkard ME .
The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS One. 2016;11(2):e0150225
[PubMed ID: 26919439]
Burkard ME Wisinski KB Njiaju UO Donohue S Hegeman R Stella A Mansky P Shah V Goggins T Qamar R Dietrich L Kim K Traynor AM Tevaarwerk AJ .
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer. 2014 Jun;14(3):205-11
[PubMed ID: 24342730]
Robins HI Burkard ME Halberg RB .
"TRIMing" the patient population to increase the benefit of mTOR inhibition. J Natl Cancer Inst. 2014 Apr 28;106(5)
[PubMed ID: 24777109]
Zasadil LM Andersen KA Yeum D Rocque GB Wilke LG Tevaarwerk AJ Raines RT Burkard ME Weaver BA .
Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014 Mar 26;6(229):229ra43
[PubMed ID: 24670687]
Rampurwala MM Rocque GB Burkard ME .
Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl). 2014;8:125-33
[PubMed ID: 25336961]
Kim H Guo F Brahma S Xing Y Burkard ME .
Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by Polo-like kinase 1 initiate Ect2 binding in early cytokinesis. Cell Cycle. 2014;13(18):2952-61
[PubMed ID: 25486482]
Choudhary A Lera RF Martowicz ML Oxendine K Laffin JJ Weaver BA Burkard ME .
Interphase cytofission maintains genomic integrity of human cells after failed cytokinesis. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13026-31
[PubMed ID: 23878225]
Lera RF Burkard ME .
High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells. J Biol Chem. 2012 Dec 14;287(51):42812-25
[PubMed ID: 23105120]
Lera RF Burkard ME .
The final link: tapping the power of chemical genetics to connect the molecular and biologic functions of mitotic protein kinases. Molecules. 2012 Oct 17;17(10):12172-86
[PubMed ID: 23075814]
Tevaarwerk A Burkard ME Wisinski KB Shafer MM Davis LA Gogineni J Crone E Hansen KE .
Aromatase inhibitors and calcium absorption in early stage breast cancer. Breast Cancer Res Treat. 2012 Jul;134(1):245-51
[PubMed ID: 22350731]
Rocque G Onitilo A Engel J Pettke E Boshoven A Kim K Rishi S Waack B Wisinski KB Tevaarwerk A Burkard ME .
Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat. 2012 Jan;131(2):713-21
[PubMed ID: 22065290]
Burkard ME Jallepalli PV .
Validating cancer drug targets through chemical genetics. Biochim Biophys Acta. 2010 Dec;1806(2):251-7
[PubMed ID: 20708654]